• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Earnings Beat Change The Bull Case For IDEXX Laboratories (IDXX)?

    Simply Wall St·10/23/2026 09:41:26
    Listen to the news
    • IDEXX Laboratories reported second quarter revenue that exceeded expectations, and management raised full year 2026 revenue guidance while expanding its menu of diagnostic tests and imaging systems.
    • The guidance upgrade highlights how IDEXX Laboratories is leaning on a broader portfolio of diagnostics and imaging tools to support recurring testing demand across its installed base.
    • We will now look at how IDEXX Laboratories' raised full year revenue guidance could reshape the existing investment narrative around recurring diagnostics.

    Scan how IDEXX Laboratories fits into the broader push for recurring diagnostics and compare it with other potential compounders across our curated 20 high quality undiscovered gems list.

    IDEXX Laboratories Investment Narrative Recap

    To own IDEXX Laboratories, you need to believe that recurring veterinary diagnostics, software and imaging can keep deepening within clinics, even as U.S. visit volumes soften. The raised 2026 revenue guidance leans into that view, because it points to demand tied to an expanding installed base rather than one off hardware. The near term swing factor remains how much testing clinics run per visit.

    The key risk still sits with growth in wellness and other discretionary visits and whether clinics adopt more premium test panels in the face of inflation. Higher spending on commercial expansion and R&D also needs to stay aligned with recurring diagnostics revenue or margin ambitions could be harder to achieve.

    The most relevant update here is IDEXX Laboratories expanding its menu of diagnostic tests and imaging systems. That directly connects to the guidance increase, because a broader test catalog can increase usage per instrument and lift consumables and service revenue across the VetLab and inVue Dx base, even if visit trends are only modestly supportive.

    For you as a shareholder, this expansion raises the stakes on execution. The more the firm leans into premium offerings such as Cancer Dx and inVue Dx panels, the more exposed it is if competitors undercut on price or veterinarians push back on adoption. The story now turns on converting that richer product suite into steady recurring revenue without letting operating costs run ahead of it.

    What The IDEXX Laboratories Targets Assume

    IDEXX Laboratories' narrative projects US$5.9b revenue and US$1.6b earnings by 2029. This implies 8.8% yearly revenue growth and an earnings increase of about US$500m from earnings today of roughly US$1.1b.

    Uncover why IDEXX Laboratories' fair value indicates a 24% potential upside to its current price before this valuation gap closes.

    NasdaqGS:IDXX 1-Year Stock Price Chart
    NasdaqGS:IDXX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts anchor their alternate IDEXX Laboratories story on much faster utilization gains per visit. Before this guidance update, they were penciling in roughly 10.1% annual revenue growth and earnings of about US$1.6b by 2029. You should treat those pre news assumptions as one possible path and compare them with other viewpoints.

    Explore 6 other IDEXX Laboratories fair value estimates, including one that suggests as much as 42% potential upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

    Looking For More IDEXX Laboratories Sized Ideas?

    If IDEXX Laboratories sharpened your thinking around recurring diagnostics and durable cash generation, widen the lens and use the Simply Wall St Screener to map out other potential opportunities that fit your preferred mix of quality, value and resilience.